Phenotyping characteristic of Tremelimumab plus MART1/DC patients segregated by responders (R) and non-responders (NR) independent of the time points.
收藏数据链接：
官方服务：
资源简介：
Early activated (CD25−HLA−DR+PD1− & CD25+HLA−DR+PD1−), n = 40 (NR) to 48 (R) time points; late activated (CD25−HLA−DR+PD1+), n = 20 (NR) to 31 (R); effectors (CCR5+CD62L+CD137−), n = 20 (NR) to 31 (R); and effectors terminally differentiated (CD45+CD56+), n = 20 (NR) to 31 (R).
创建时间：
2015-12-02
